Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress

Poolbeg Pharma raised £3.5 million before expenses via a share placing, with executive chair Cathal Friel subscribing £250,000. The update is incremental for a clinical-stage biotech, with limited disclosed operational impact beyond securing near-term funding.

Analysis

Poolbeg Pharma raised £3.5 million before expenses via a share placing, with executive chair Cathal Friel subscribing £250,000. The update is incremental for a clinical-stage biotech, with limited disclosed operational impact beyond securing near-term funding.